Patient Square Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001819257

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 23 positions · Total reported value $626.68M · Top-10 concentration 80.6% · Updated 2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.0% · 6 new · 8 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Patient Square Capital LP disclosed 23 equity positions with a combined reported value of $626.68M. The filing implies a focused portfolio: its ten largest positions account for 80.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ROIV ($281.99M), RVMD ($40.23M), UTHR ($33.96M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+2.3pp) and away from Other (-0.7pp), Industrials (-1.6pp).

Versus the prior quarter, Patient Square Capital LP opened 6 new positions, trimmed 8 and fully exited 6, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q3 2026 were ZLAB ($15.58M), DFTX ($14.65M), CMPS ($13.14M).

Of the 6 positions fully exited versus the prior quarter, the largest were XENE ($13.28M), DNTH ($10.53M), EYPT ($10.30M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ZLAB ZAI LAB LTD · $15.58M
  • DFTX DEFINIUM THERAPEUTICS INC · $14.65M
  • CMPS COMPASS PATHWAYS PLC · $13.14M
  • PCVX VAXCYTE INC · $9.45M
  • ZNTL ZENTALIS PHARMACEUTICALS INC · $5.56M
  • HROW HARROW INC · $4.47M

Fully Exited (vs previous quarter)

  • XENE XENON PHARMACEUTICALS INC · prev qtr: $13.28M
  • DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $10.53M
  • EYPT EYEPOINT INC · prev qtr: $10.30M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · prev qtr: $9.70M
  • CCCC C4 THERAPEUTICS INC · prev qtr: $7.51M
  • FTH FAETH THERAPEUTICS INC · prev qtr: $4.38M

Insider Transactions (Form 4)

Latest Patient Square Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Patient Square Capital LP is a Menlo Park, CA-based investment firm founded by David Goel and Stephen Mandel Jr. with approximately $17.5 billion in assets under management.

Investment Approach

They employ a long-term, concentrated investment strategy focusing on high-quality companies with strong competitive advantages.

Asset Classes

Primarily invests in US equities, as evidenced by their SEC Form 13F filings.

Notable Facts

Founded in 2016, known for activist investment style, sometimes taking significant positions in companies and advocating for changes.

Key People

Founded by David Goel and Stephen Mandel Jr. (co-founder of Lone Pine Capital).

For official disclosures, refer to the firm's SEC filings.

AI Rebalance Analysis

1. Overall direction and market view: The fund is selectively reducing exposure to large positions (ROIV, RVMD, MIRM) while adding to smaller holdings (UTHR, ARGX, PHVS, ABVX, BLTE) and initiating new positions (ZLAB, DFTX), suggesting a cautious but opportunistic stance on biotech/healthcare with a focus on undervalued or high-potential names. 2. Key moves: - Reduced: ROIV (-3.9% shares), RVMD (-29.0% shares), MIRM (-10.2% shares). - Added: UTHR (+68.8% shares), ARGX (+21.7% shares), PHVS (+20.5% shares), ABVX (+17.7% shares), BLTE (+19.7% shares). - New: ZLAB, DFTX (no prior holdings). 3. Portfolio structure: Active, concentrated (top 10 = 80.7%), heavily biased toward Health Care (100%), with moderate risk appetite (mix of large caps and speculative biotechs). 4. Per-holding one-liner: - ROIV: Roviant Sciences (biopharma, unverified). - RVMD: Revolution Medicines (cancer therapeutics, unverified). - UTHR: United Therapeutics (pulmonary hypertension, unverified). - ARGX: Argenx (immunology, unverified). - PHVS: Pharvaris (orphan drugs, unverified). - ABVX: Abivax (viral diseases, unverified). - BLTE: Belite Bio (eye diseases, unverified). - MIRM: Mirum Pharmaceuticals (liver diseases, unverified). - ZLAB: Zai Lab (oncology/immunology, unverified). - DFTX: Definium Therapeutics (gene therapy, unverified). 5. Style summary: "Selective biotech fund trimming large positions to capitalize on undervalued and emerging healthcare opportunities."

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-14 21:38

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 7.71M $281.99M 45.00%
45.00%
Reduce
2 196.00K $40.23M 6.42%
6.42%
Reduce
3 62.68K $33.96M 5.42%
5.42%
Add
4 28.00K $26.85M 4.28%
4.28%
Add
5 808.64K $25.65M 4.09%
4.09%
Add
6 243.00K $24.06M 3.84%
3.84%
Add
7 131.70K $22.37M 3.57%
3.57%
Add
8 234.00K $20.00M 3.19%
3.19%
Reduce
9 591.51K $15.58M 2.49%
2.49%
New
10 385.00K $14.65M 2.34%
2.34%
New
11 1.06M $13.14M 2.10%
2.10%
New
12 1.11M $13.00M 2.08%
2.08%
Add
13 33.50K $12.26M 1.96%
1.96%
Reduce
14 361.93K $11.59M 1.85%
1.85%
Reduce
15 410.00K $10.59M 1.69%
1.69%
Add
16 105.42K $10.36M 1.65%
1.65%
Reduce
17 212.50K $9.74M 1.55%
1.55%
Hold
18 166.00K $9.45M 1.51%
1.51%
New
19 84.00K $9.39M 1.50%
1.50%
Add
20 4.55M $7.28M 1.16%
1.16%
Reduce
21 2.01M $5.56M 0.89%
0.89%
New
22 1.22M $4.51M 0.72%
0.72%
Reduce
23 145.00K $4.47M 0.71%
0.71%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 23% of its Top-10 each quarter and backtests at F1 68% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 74% · recall 66% · F1 68% · avg rank error 2.6 · Top-10 turnover 23%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 50% 50% 50% ROIV · EAR ROIV · LQDA
2024-Q2 100% 100% 100% ROIV · LQDA ROIV · LQDA
2024-Q3 100% 20% 33% ROIV · LQDA ROIV · LQDA · CGEM · INSM · EYPT · NRIX · PHVS · NTLA · ELVN · OCUL
2024-Q4 80% 80% 80% ROIV · LQDA · CGEM · INSM · EYPT · NRIX · PHVS · NTLA · ELVN · OCUL ROIV · LQDA · INSM · CGEM · EYPT · NRIX · ITCI · ELVN · GERN · OCUL
2025-Q1 80% 80% 80% ROIV · INSM · LQDA · CGEM · EYPT · NRIX · ITCI · ELVN · GERN · OCUL ROIV · INSM · LQDA · EYPT · OCUL · CGEM · NRIX · MIRM · ELVN · SRRK
2025-Q2 80% 80% 80% ROIV · INSM · LQDA · EYPT · OCUL · CGEM · MIRM · ELVN · SRRK · NRIX ROIV · INSM · ARGX · EYPT · LQDA · OCUL · CGEM · KYMR · MIRM · SRRK
2025-Q3 70% 70% 70% ROIV · INSM · ARGX · EYPT · LQDA · OCUL · CGEM · MIRM · SRRK · KYMR ROIV · INSM · EYPT · ABVX · CDTX · ARGX · LQDA · PHVS · OCUL · MIRM
2025-Q4 70% 70% 70% ROIV · INSM · EYPT · CDTX · ABVX · ARGX · PHVS · OCUL · LQDA · MIRM ROIV · INSM · MIRM · ARGX · ONC · ABVX · PHVS · EYPT · TERN · CELC
2026-Q1 50% 50% 50% ROIV · INSM · MIRM · ARGX · ONC · ABVX · PHVS · EYPT · TERN · CELC ROIV · ARGX · INSM · ONC · COGT · MIRM · BLTE · LEGN · NKTR · DBVT
2026-Q2 60% 60% 60% ROIV · ARGX · COGT · ONC · MIRM · INSM · BLTE · LEGN · DBVT · NKTR ROIV · RVMD · MIRM · ABVX · ONC · PHVS · ARGX · UTHR · BLTE · COGT
2026-Q3 ★ 70% 70% 70% ROIV · RVMD · MIRM · ABVX · ONC · PHVS · ARGX · UTHR · COGT · DBVT ROIV · RVMD · UTHR · ARGX · PHVS · ABVX · BLTE · MIRM · ZLAB · DFTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-12. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-12 Trading days31 Holdings5 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-12, and will update as prices arrive.

Portfolio return+10.56%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return+21.71%vs benchmark
Barra annualised vol46.2%Model estimate
Realised vol39.8%Annualised in window
Weighted beta0.86Raw exposure
Factor / specific risk46% / 54%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)77.886.695.4104.2113.010-0110-2211-12Patient Square Capital LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+10.56%Disclosed long book
QQQ synthetic benchmark-11.15%Liquidity-weighted constituents
Model universe, equal weight+2.04%Opportunity-cost reference
Excess return+21.71%Portfolio − benchmark
Arithmetic return sum+10.99%Difference vs compounded is the cross term
Weighted raw beta0.86Weighted holding betas
Realised volatility (annualised)39.83%Daily returns in window
Barra model volatility (annualised)46.21%Factor + specific
Factor share of variance46.0%Barra factors
Specific share of variance54.0%Stock residuals
Reported value$395.3M13F long US equity

2. Return attribution

The +10.99% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +0.24% 2.2%
Momentum & Growth 3 -7.08% -64.4%
Volatility & Tail Risk 7 +1.33% 12.1%
Industry 12 +9.47% 86.1%
Specific 1 +7.03% 64.0%
Return attribution (style + industry, %)-15.3-7.6+0.0+7.6+15.3Short-term Reversal-0.27Liquidity-0.33Amihud Illiquidity+0.42Mid Cap-0.78Residual Volatility+0.99Max Drawdown-1.18Turnover-1.42Size+2.27Leverage (Downside Vol)+2.44Historical Volatility-4.13Momentum-6.58Health Care+9.47Skewness-10.89Kurtosis+14.15
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +2.29 +6.17% +14.15% 128.7%
Health Care Industry +1.00 +9.47% +9.47% 86.1%
Specific Specific — — +7.03% 64.0%
Leverage (Downside Vol) Style -0.80 -3.05% +2.44% 22.2%
Size Style -1.18 -1.93% +2.27% 20.6%
Residual Volatility Style +0.46 +2.15% +0.99% 9.0%
Amihud Illiquidity Style +1.41 +0.30% +0.42% 3.9%
Non-linear Size Style +1.15 +0.07% +0.08% 0.7%
Growth Style -0.15 +1.50% -0.23% -2.1%
Short-term Reversal Style -0.24 +1.12% -0.27% -2.4%
Liquidity Style +1.63 -0.20% -0.33% -3.0%
Mid Cap Style +0.40 -1.92% -0.78% -7.0%
Max Drawdown Style +1.16 -1.01% -1.18% -10.7%
Turnover Style +0.33 -4.35% -1.42% -12.9%
Historical Volatility Style +0.42 -9.82% -4.13% -37.6%
Momentum Style +1.98 -3.32% -6.58% -59.9%
Skewness Style +2.28 -4.77% -10.89% -99.0%

3. Risk attribution

Annualised volatility is 46.21%; factor risk explains 46.0% of variance and specific risk 54.0%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-58.3-29.2+0.0+29.2+58.3Non-linear Size-1.62Leverage (Downside Vol)-1.36Historical Volatility-1.11Turnover+0.32Residual Volatility+0.82Max Drawdown+1.20Amihud Illiquidity+1.55Size+2.98Liquidity+4.83Skewness+6.48Kurtosis+6.49Momentum+12.42Health Care+12.54Specific+54.02
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 54.0% +24.96% 25.0%
Health Care Industry +1.00 12.5% +5.80% 5.8%
Momentum Style +1.98 12.4% +5.74% 5.7%
Kurtosis Style +2.29 6.5% +3.00% 3.0%
Skewness Style +2.28 6.5% +2.99% 3.0%
Liquidity Style +1.63 4.8% +2.23% 2.2%
Size Style -1.18 3.0% +1.38% 1.4%
Amihud Illiquidity Style +1.41 1.6% +0.72% 0.7%
Max Drawdown Style +1.16 1.2% +0.55% 0.6%
Residual Volatility Style +0.46 0.8% +0.38% 0.4%
Turnover Style +0.33 0.3% +0.15% 0.1%
Historical Volatility Style +0.42 -1.1% -0.51% -0.5%
Leverage (Downside Vol) Style -0.80 -1.4% -0.63% -0.6%
Non-linear Size Style +1.15 -1.6% -0.75% -0.8%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.5-0.50.61.62.6Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.18 +2.10 -3.28
Non-linear Size +1.15 +1.68 -0.53
Mid Cap +0.40 +0.13 +0.28
Beta -0.01 +1.29 -1.30
Momentum +1.98 +0.72 +1.27
Short-term Reversal -0.24 -0.64 +0.40
Residual Volatility +0.46 -0.40 +0.86
Historical Volatility +0.42 +0.86 -0.44
Liquidity +1.63 +0.11 +1.52
Amihud Illiquidity +1.41 +1.16 +0.26
Turnover +0.33 +0.21 +0.12
Growth -0.15 +0.58 -0.74
Leverage (Downside Vol) -0.80 +0.14 -0.95
Skewness +2.28 +0.24 +2.04
Kurtosis +2.29 +0.21 +2.08
Max Drawdown +1.16 -0.08 +1.25

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -16.67% +4.61% +12.27% -12.27% +12.27%
Health Care 100.0% 1.7% +10.52% +9.50% +19.56% +0.02% +1.01% +10.36%
Communication Services 0.0% 2.6% +0.00% -12.15% +0.05% +0.32% -0.32% +0.32%
Utilities 0.0% 0.8% +0.00% +10.14% -0.16% -0.08% +0.08% -0.08%
Consumer Staples 0.0% 0.8% +0.00% +15.33% -0.22% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.93% -1.44% -0.52% +0.52% -0.52%
Industrials 0.0% 11.1% +0.00% +7.87% -2.03% -0.87% +0.87% -0.87%
Total +20.28% +10.97% -9.94% +21.31%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
ROIV ROIVANT SCIENCES LTD Health Care 71.34% +14.44% +10.30% Reduce
RVMD REVOLUTION MEDICINES INC Health Care 10.18% -11.96% -1.22% Reduce
UTHR UNITED THERAPEUTICS CORP DEL Health Care 8.59% +9.92% +0.85% Add
ARGX Argenx S.E. Health Care 6.79% +1.95% +0.13% Add
ONC BEONE MEDICINES LTD Health Care 3.10% +14.77% +0.46% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 ROIV Health Care 71.34% +14.44% +10.30%
2 UTHR Health Care 8.59% +9.92% +0.85%
3 ONC Health Care 3.10% +14.77% +0.46%
4 ARGX Health Care 6.79% +1.95% +0.13%
5 RVMD Health Care 10.18% -11.96% -1.22%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-12 (31 trading days), the reported portfolio returned +10.56%, versus -11.15% for the QQQ synthetic benchmark — an excess of +21.71%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +14.15%, Health Care +9.47%, Leverage (Downside Vol) +2.44%; the largest drags came from Skewness -10.89%, Momentum -6.58%, Historical Volatility -4.13%. Specific (stock-level) return contributed +7.03%.
  3. Risk attribution: Barra model volatility is 46.21% annualised; factor risk explains 46% of variance and specific risk 54%. The largest factor risk sources are Health Care 12.5%, Momentum 12.4%, Kurtosis 6.5%.
  4. Style tilt: size -1.18, momentum +1.98, volatility +0.42, liquidity +1.63; the weighted raw beta is 0.86. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.28%, selection +10.97% and interaction -9.94%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Patient Square Capital LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Patient Square Capital LP reported 23 equity positions worth $626.68M in aggregate; its largest disclosed positions were ROIV ($281.99M), RVMD ($40.23M), UTHR ($33.96M).

How large is Patient Square Capital LP's portfolio?

Patient Square Capital LP reported $626.68M of long equity holdings across 23 positions as of 2026-Q3. Top-10 holdings account for 80.6% of reported value.

What is Patient Square Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/patient-square-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →